Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleCrunchbase News

The Rising Investors Behind The New Unicorn Class

View original at news.crunchbase.com
Crunchbase News - Funding Ma Title: The Rising Investors Behind The New Unicorn Class Date: 2026-03-17 11:00 Source: https://news.crunchbase.com/venture/unicorn-investment-momentum-ai-sequoia-a16z-2025/ <p>The race to back the next generation of billion-dollar startups accelerated last year as the stable of unicorn sta…
Opening lines of the source · Crunchbase News · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Cutting-edge companies in today's market risk being taken over by AI developments which erode their advantage and wipe away their lead

    60% confidence

  • The pace of new unicorn creation picked up each quarter in 2025 and has shown no signs of slowing in 2026

    60% confidence

  • Nearly half of the new unicorns are very young: 94 of them are less than 5 years old

    60% confidence

  • 187 companies joined The Crunchbase Unicorn Board in 2025, up 61% from the previous year, driven largely by the AI boom

    60% confidence

  • AI-native companies accounted for 47 of last year's new unicorns, or 25% of the total

    60% confidence

  • Investors who want to back the next market winners need to keep investing

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com